|1.||Louda, N: 1 article (01/2001)|
|2.||Keil, F: 1 article (01/2001)|
|3.||Karlic, H: 1 article (01/2001)|
|4.||Lohninger, A: 1 article (01/2001)|
|5.||Pittermann, E: 1 article (01/2001)|
|6.||Pfeilstöcker, M: 1 article (01/2001)|
|7.||Paukovits, J: 1 article (01/2001)|
08/01/1991 - "Clinically relevant data are available for pEEDCK, showing that application of this peptide leads to a delayed, shorter, and less severe neutropenia, combination of pEEDCK with a stimulator avoids neutropenia, and stem cell preservation with pEEDCK improves long-term reconstitution of the haematopoietic system. "
03/15/1991 - "A single injection of 30 micrograms/kg pEEDCK monomer to mice 2 hours before the second Ara-C injection retarded onset of neutropenia (by 2 to 3 days) and improved recovery after depression. "
01/01/1991 - "Inhibition of hematopoietic stem cell proliferation by hemoregulatory peptide pyroGlu-Glu-Asp-Cys-Lys (pEEDCK) provides protection against short-term neutropenia and long-term damage."
09/01/1990 - "(a) ara-monomer-ara: The administration of pEEDCK-monomer 2 h before the second ara-C injection retarded the onset of neutropenia, shortened its duration and improved recovery after depression. "
09/01/1990 - "pEEDCK could play a role as hemoprotector in tumor chemotherapy. "
09/01/1990 - "The hemoregulatory peptide (pGlu-Glu-Asp-Cys-Lys, pEEDCK) is a potent inhibitor of stem cell recruitment, which is a major source of hematological complications after cytostatic tumor therapy. "
06/01/1995 - "This paper will review the present knowledge on two small chemically unrelated peptides, the pentapeptide pGlu-Glu-Asp-Cys-Lys (pEEDCK) and the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP, Seraspenide) focusing on 1) their inhibitory effects on normal hematopoiesis, 2) their effect on malignant cells, especially leukemic cells, and 3) their potential clinical use as marrow protectors during cancer therapy."
|3.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/01/2001 - "Effect of the hemoregulatory peptide (pEEDCK)2 (pyroGlu-Glu-Asp-Cys-Lys)2 and MIP-1alpha is reduced in bone marrow cultures from patients with chronic myeloid leukemia (CML)."
01/01/2001 - "When long-term bone marrow cultures (LTBMCs) were incubated with (pEEDCK)2 or MIP-1alpha and/or cytokines, the stimulatory effect on colony-forming units-granulocyte/erythroid/macrophage/megakaryocyte of LTBMC from chronic myeloid leukemia (CML) patients was less than 50% compared to LTBMC from healthy humans. "
08/01/1991 - "Marie-Hélène Moser and Walter Paukovits discuss how it should be possible to minimize such proliferation-associated damage by inhibiting CFU-S during the most dangerous treatment phases, with factors such as transforming growth factor beta, tumour necrosis factor alpha, macrophage inflammatory protein 1 alpha, and the CFU-S-inhibitory peptides N-acetyl-Ser-Asp-Lys-Pro and pyroGlu-Glu-Asp-Cys-Lys (pEEDCK). "
08/01/1998 - "Because many in vivo situations (e.g., infection) requiring increased hematopoiesis involve granulocyte and macrophage activation, the formation of dimer from endogenous pEEDCK monomer may provide an almost instantaneous demand-induced emergency signal for increasing stem cell proliferation and blood cell production."
|7.||Transforming Growth Factor beta (TGF-beta)
|1.||Drug Therapy (Chemotherapy)